NEW YORK, Dec. 8 /PRNewswire-FirstCall/ -- Pfizer Inc announced today that the Canadian Federal Court in Toronto has granted its application for an order preventing Novopharm Ltd. from launching a generic version of Lipitor until expiration of the product's patent (Canadian Patent 2,021,546) in July, 2010. The decision is subject to appeal.
"This is yet another decision recognizing the protection of the intellectual property supporting Lipitor," said Pfizer General Counsel Allen Waxman. "Patents like this one provide the incentive to develop new, life- saving medicines that benefit millions of patients globally and Pfizer will continue to vigorously defend its intellectual property rights wherever they are challenged."
Photo: A free corporate logo to accompany this story is availableimmediately via Wieck Photo Database to any media with telephoto receiveror electronic darkroom, PC or Macintosh, that can accept overheadtransmissions. To retrieve a logo, please call 972-392-0888.Pfizer IncCONTACT: Bryant Haskins, +1-212-733-8719
Web site: http://www.pfizer.com/
